Redigerer Favipiravir (avsnitt)

===Ebola===
Forskning i 2014 mente at Favipiravir kunne ha en effekt mot [[Ebola]] basert på studier på mus [[modellorganisme|som forsøksmetode]]; effisiens hos mennesker var ikke tematisert.<ref name="Gatherer 2014">{{cite journal | vauthors = Gatherer D | title = The 2014 Ebola virus disease outbreak in West Africa | journal = The Journal of General Virology | volume = 95 | issue = Pt 8 | pages = 1619–1624 | date = August 2014 | pmid = 24795448 | doi = 10.1099/vir.0.067199-0 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S | title = Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model | journal = Antiviral Research | volume = 105 | issue =  | pages = 17–21 | date = Mai 2014 | pmid = 24583123 | doi = 10.1016/j.antiviral.2014.02.014 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS | title = Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model | journal = Antiviral Research | volume = 104 | pages = 153–5 | date = April 2014 | pmid = 24462697 | doi = 10.1016/j.antiviral.2014.01.012 }}</ref>

Under [[ebolaepidemien i Vest-Afrika]] i 2014 ble det meldt at en fransk sykepleier fra [[Médecins Sans Frontières]] (MSF) i Liberia og som var blitt smittet av ebola, tilfrisknes etter å ha blitt behandlet med favipiravir.<ref>{{cite news|title=First French Ebola patient leaves hospital|url=https://www.reuters.com/article/us-health-ebola-france-idUSKCN0HT0D720141004|work=Reuters|date=4. oktober 2016}}</ref> Kriniske undersøkelser av favipiravir brukt mot ebolavirussykdom begynte i  [[Guéckédou]] i [[Guinea]] i desember 2014.<ref>{{cite web|title=Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea|url=http://allafrica.com/stories/201412260651.html|publisher=AllAfrica – All the Time|access-date=28. desember 2014}}</ref> Preliminære resultater fremlagt i 2016 på [[Conference on Retroviruses and Opportunistic Infections]] (CROI) og senere publisert, viste en nedgang i mortalitet hos pasienter med lave-til-moderate nivåer av virus i blodet, men ingen effekt når nivåene var høye (hos pasienter med høyere risiko for en dødelig utgang).<ref>{{Cite web|url=http://www.croiconference.org/sessions/favipiravir-patients-ebola-virus-disease-early-results-jiki-trial-guinea|title=Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea|work=CROIconference.org|access-date=2016-03-17}}</ref><ref>{{cite journal | vauthors = Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Kighoma PM, Koundouno FR, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Dortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D | display-authors = 6 | title = Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea | journal = PLOS Medicine | volume = 13 | issue = 3 | pages = e1001967 | date = Mars 2016 | pmid = 26930627 | pmc = 4773183 | doi = 10.1371/journal.pmed.1001967 }}</ref><ref>{{cite news| url=https://www.nytimes.com/2015/02/05/science/ebola-drug-has-encouraging-early-results-and-questions-follow.html | work=[[The New York Times]] | first=Sheri | last=Fink | name-list-format = vanc | title=Ebola Drug Aids Some in a Study in West Africa | date=4. februar 2015}}</ref> Måten forsøket var satt opp på ble samtidig kritisert for bare å benytte historiske kontroller.<ref>{{cite journal |url= http://www.sciencemag.org/news/2015/02/results-encouraging-ebola-trial-scrutinized |title=Results from encouraging Ebola trial scrutinized | first = Jon | last = Cohen | name-list-format = vanc |journal=[[Science (journal)|Science]] |date=26. februar 2015 |access-date= 21. januar 2016 |doi=10.1126/science.aaa7912}}</ref>